Clinical trial NCT03889457: What Treatment for Patients With Phlebitis or Pulmonary Embolism ?
Official title: Patients' Choice in Terms of Anticoagulant Therapy in Venous Thrombo- Embolism Disease. AntiCoagChoice Study
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Venous Thrombosis or Pulmonary Embolism
Keywords: Deep Vein Thrombosis
Superficial Vein Thrombosis
Anticoagulant
Patient Compliance
Preference
Venous Thrombosis
pulmonary embolism
Lead sponsor: Rennes University Hospital
Sponsor class: OTHER
Collaborators: name: SFMV (French Society of Vascular Medicine)
First posted: 2019-03-26
Enrollment: 1000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with deep vein thrombosis, superficial vein thrombosis, muscle vein thrombosis or pulmonary embolism, over 18 years of age in France (via the vascular doctors of the French Society of Vascular Médicine).

Brief summary: The objective of the "anticoagchoice" study is to analyze the preferences of people suffering from phlebitis, in terms of anticoagulant, to improve adherence to these treatments, to adapt the medical prescriptions.

Detailed description: Venous thromboembolism (VTE) is the third leading cause of cardiovascular death, with an increase in annual incidence with age. With the advent of direct oral anticoagulants, the management of deep vein thrombosis and pulmonary embolism has evolved in recent years and these treatments are widely prescribed. There are studies comparing the different anticoagulant treatments used in venous thrombosis, which show no inferiority of treatment (injectable or oral) compared to others. Drug delivery modalities have been shown to affect adherence, and thus treatment efficacy. It seems fundamental to focus on patients' drug preferences in VTE to ensure the best possible compliance. These preferences seem to depend on the personal history of each patient. In addition, no studies have been conducted on patient preferences for anticoagulant therapy for VTE: this is the goal of the "anticoagchoice" study.

Eligibility criteria: Inclusion Criteria:

* Patients with deep vein thrombosis, superficial vein thrombosis, muscle vein thrombosis or pulmonary embolism, over 18 years of age.

No Exclusion Criteria

Primary outcomes:
measure: The primary objective of this study is to analyze patient treatment preferences in venous thromboembolic disease.
timeFrame: the time required for a consultation: 30 minutes
Secondary outcomes:
measure: compare patients choosing oral anticoagulation vs patients choosing an injectable route
timeFrame: the time required for a consultation: 30 minutes
measure: compare patients choosing oral anticoagulation vs patients choosing an injectable route
timeFrame: the time required for a consultation: 30 minutes
Other outcomes:
Locations:
city: Rennes
country: France
facility: Rennes University Hospital
Study officials:
affiliation: Rennes University Hospital
name: Guillaume Mahe
role: PRINCIPAL_INVESTIGATOR
References:
citation: Laneelle D, Le Brun C, Mauger C, Guillaumat J, Le Pabic E, Omarjee L, Mahe G; SFMV VTE Study Group. Patient Characteristics and Preferences Regarding Anticoagulant Treatment in Venous Thromboembolic Disease. Front Cardiovasc Med. 2021 Jun 21;8:675969. doi: 10.3389/fcvm.2021.675969. eCollection 2021.